The impact of platelet function inhibition on circulating cancer cells in metastatic breast cancer patients.

Trial Profile

The impact of platelet function inhibition on circulating cancer cells in metastatic breast cancer patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 24 Jan 2017 Status changed from completed to discontinued due to low percentage of patients with detectable CTCs at baseline.
    • 18 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jun 2012 Planned end date changed from 1 Aug 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top